DURVALUMAB ( ASTRAZENECA ) // ATEZOLIZUMAB ( ROCHE ) SEGUNDA LÍNEA SCLC . A Retrospective Real-World Experience of Immunotherapy in Patients With Extensive Stage Small-Cell Lung Cancer .

 

La SG de los Pacientes con ES-SCLC Que Recibieron Inmunoterapia Como Tratamiento de SEGUNDA LÍNEA Fue Mejor Que la del Grupo de Quimioterapia (15,9 Meses Frente a 12,9 Meses, p  = 0,036) .

El Presente Estudio Mostró Que la ICI COMBINADA con Quimioterapia con ETOPÓSIDO y CISPLATIN Como Tratamiento de FL ( FIRST LINE ) Podría Prolongar la SLP y la SG de los Pacientes con ES-SCLC .

Post By Wiley Online Library : 18 JULY 2023 .

The Treatment of Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Has Only Made Modest Progress in The Past Decade, With Two Immune Checkpoint Inhibitors (ICIs), ATEZOLIZUMAB ( TECENTRIQ  By ROCHE ) and DURVALUMAB ( IMFINZI By ASTRAZENECA ),  Approved For The Treatment Of SCLC By January 2022 .

 However, Currently, There is Limited Real-World Data on ES-SCLC Patients Received Immunotherapy .

Methods :

We Retrospectively Collected and Qnalyzed the Demographic and Treatment Data of ES-SCLC Patients at The First Affiliated Hospital of Guangzhou Medical University from January 2017 to January 2022 .

 Survival and Prognosis Information Was Obtained Through Follow-up .

Results :

A Total of 353 ES-SCLC Patients Were Included, of Which 165 Received Immunotherapy Combined With Chemotherapy as the FIRST-LINE (FL) Treatment (chemo-immune group), and 188 received Chemotherapy ( Chemotherapy Group ). 

The Objective Response Rate (ORR) and Disease Control Rate (DCR) of Patients Receiving Immunotherapy as The FL Treatment Were Better Than the Chemotherapy Group (76.97% vs. 48.40%, p < 0.001, and 83.03% vs. 68.09%, p < 0.001) .

Moreover, The PROGRESSION-FREE SURVIVAL (PFS) and OVERALL SURVIVAL (OS) of ES-SCLC Patients Receiving Immunotherapy as the FL Treatment Were Better Than the Chemotherapy Group (6.7 Months vs. 5.1 Months, p < 0.001, and 12.5 Months vs. 11.2 Months, p < 0.001).

 Furthermore, The OS of ES-SCLC Patients Who Received Immunotherapy as SECOND-LINE Treatment Was Better Than That in The Chemotherapy Group (15.9 Months vs. 12.9 Months, p = 0.036) .

Conclusion :

ICIs Combined With CHEMOTHERAPY as The FL Treatment Could be Beneficial to the ORR, DCR, PFS, and OS of ES-SCLC Patients .

 Furthermore, ES-SCLC Patients Can Benefit From ICIs in The SECOND-LINE Treatment, Even if They Had Not Received ICIs in the FL Treatment .